Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uterine Cervical Neoplasms 1Lung Neoplasms 1Leiomyoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 5Interviews as Topic 4Early Intervention, Educational 4Cisplatin 4Blood Specimen Collection 4pembrolizumab 3cemiplimab 3atezolizumab 3Radiosurgery 3Methods 3Injections 3Etoposide 3durvalumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiation 2PM 01183 2Observation 2Nivolumab 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × DMAC2L protein, human × Clear all
NCT07463677 2026-03-11

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡